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Abstract
Introduction: Hyperglycemia and insulin resistance are commonplace in critical illness, especially in patients with
sepsis. Recently, several hormones secreted by adipose tissue have been determined to be involved in overall
insulin sensitivity in metabolic syndrome-related conditions, including adipocyte fatty-acid binding protein (A-
FABP). However, little is known about their roles in critical illness. On the other hand, there is evidence that several
adipose tissue gene expressions change in critically ill patients.
Methods: A total of 120 patients (72 with sepsis, 48 without sepsis) were studied prospectively on admission to a
medical ICU and compared with 45 healthy volunteers as controls. Various laboratory parameters and metabolic
and inflammatory profiles were assessed within 48 hours after admission. Clinical data were collected from medical
records.
Results: Compared with healthy controls, serum A-FABP concentrations were higher in all critically ill patients, and
there was a trend of higher A-FABP in patients with sepsis. In multivariate correlation analysis in all critically ill
patients, the serum A-FABP concentrations were independently related to serum creatinine, fasting plasma glucose,
total cholesterol, TNF-alpha, albumin, and the Acute Physiology and Chronic Health Evaluation II scores. In survival
analysis, higher A-FABP levels (> 40 ng/ml) were associated with an unfavorable overall survival outcome, especially
in sepsis patients.
Conclusions: Critically ill patients have higher serum A-FABP concentrations. Moreover, A-FABP may potentially
serve as a prognostic biomarker in critically ill patients with sepsis.
Introduction
Intensive stress responses are common in critically ill
patients who face life-threatening situations. These
responses include inflammatory and metabolic compo-
nents. They activate central nervous system and neu-
roendocrine axes, increasing the release of cortisol,
epinephrine, norepinephrine, growth hormone, gluca-
gon, and several cytokines [1]. The typical clinical pic-
ture is hyperglycemia and insulin resistance. Acute
stress-induced hyperglycemia is observed in many clini-
cal conditions, such as myocardial infarction, stroke,
trauma, and in critically ill surgical patients [2-5]. The
causal relationships between hyperglycemia, insulin
treatment, and prognosis have been the focus of atten-
tion in recent years [6].
Increasing evidence shows that adipose tissue plays a
key role in the development of metabolic syndrome
(MS) via the secretion of a variety of adipokines [7].
These adipokines include adiponectin, leptin, resistin
and visfatin, among others. Studies of these adipokines
have revealed a well-established link between adipose
tissue, inflammation, and insulin resistance [8]. Because
many acute metabolic changes seen in critically ill
patients are similar to those seen in patients with MS, it
is believed that such changes are also involved in the
acute stress responses associated with critical illness [9].
Adipocyte fatty-acid binding protein (A-FABP) is one of
the most abundant intracellular lipid transport proteins in
mature adipocytes and macrophages. The expression is
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regulated by fatty acids, peroxisome proliferator-activated
receptor g agonists, lipopolysaccharide (LPS), oxidized low
density lipoprotein and advanced glycation end products
[10]. A-FABP-deficient mice exhibited reduced hyperinsu-
linemia and insulin resistance in the context of both diet-
ary and genetic obesity, which might be caused by
decreased TNF-alpha expression, enhanced insulin recep-
tor signaling and muscle AMP-activated kinase activity
[11]. A-FABP has also been shown to regulate many
inflammatory cytokines in vivo and in vitro [12]. However,
data from both rodents and humans suggest that it is also
secreted by adipose tissue into the bloodstream [13].
Recent studies have confirmed its roles in various condi-
tions associated with insulin resistance, including MS, dia-
betes mellitus, nonalcoholic fatty liver disease, Cushing’s
syndrome, and polycystic ovary disease [14-18]. The aim
of our study was to evaluate the correlations between
A-FABP, systemic inflammation, and insulin resistance
associated with critical illness, and further to investigate its
role in outcome prediction.
Materials and methods
Study design
A total of 120 patients (74 male, median age 74 years) was
prospectively enrolled at the time of medical ICU admis-
sion in 2011. Patients currently undergoing regular hemo-
dialysis, with acute myocardial infarction, who refused
intensive therapy, or who were expected to stay < 72
hours in the ICU (for example, for post-interventional
observation, acute intoxication) were excluded from the
study. Written informed consent was obtained from each
participant or from his or her family member, and the
study was approved by the Institutional Review Board of
the Taoyuan General Hospital. Patient data and clinical
information, including Acute Physiology and Chronic
Health Evaluation II (APACHE II) score, vasopressor
demand, ventilator use or not, and total ICU and hospital
days, were collected from medical records. Blood samples
were collected within 48 hours of ICU admission. Patients
with critical illness were divided into two groups: sepsis
patients and non-sepsis patients. Sepsis was defined as the
presence of systemic inflammatory response syndrome
associated with infection confirmed or strongly suspected,
according to criteria proposed by the American College of
Chest Physicians and the Society of Critical Care Medicine
Consensus Conference Committee for severe sepsis and
septic shock [19]. Insulin resistance was calculated by the
homeostasis model assessment (HOMA) method. Serum
A-FABP concentrations were analyzed by ELISA accord-
ing to the manufacturer’s instructions. The median length
of stay in the ICU was 7 days, and the median length of
stay in hospital was 15 days.
The control group consisted of 45 age- and gender-
matched healthy subjects with normal blood counts, renal
function, and C-reactive protein (CRP) levels who were
recruited from a health examination center.
Statistical analysis
Because of the skewed distribution of most parameters in
patients with a critical illness, data are given as median
and IQRs (Table 1). Differences between two groups were
assessed by the Mann-Whitney U test. Correlations
between variables were analyzed using Spearman’s correla-
tion coefficient. The prognostic value of the variables was
tested by univariate and multivariate analyses using a Cox
regression model. Kaplan-Meier curves were plotted to
display the impact on survival. Analyses were performed
using STATA statistical software (release 10.0, StataCorp
LP, Texas, USA). All statistical tests were two-sided, and
P values < 0.05 were considered statistically significant.
Results
Among the 120 critically ill patients enrolled in this study,
72 met the criteria for sepsis (Table 1). In the majority of
sepsis patients, the origin of infection was identified as
pneumonia, urinary tract infection or intra-abdominal
infection (Table 2). Non-sepsis patients did not differ from
sepsis patients in terms of age or sex, and were admitted
due to cardiopulmonary disorders (chronic obstructive
pulmonary disease, asthma and cardiac pulmonary
edema), cerebrovascular disease, decompensated liver dis-
ease, or other critical conditions. Among all critically ill
patients, 11.7% died in the ICU and 16.7% died before dis-
charge. Patients with sepsis clearly had a higher ICU and
hospital mortality rate than non-sepsis patients (P = 0.008
and 0.01, respectively).
Compared with healthy volunteers, patients with critical
illness had higher serum A-FABP levels (median 43.3 ng/
ml in patients versus 19.3 ng/ml in controls; P < 0.0001).
Subgroup analysis of septic and non-septic patients
showed a trend of higher A-FABP serum levels in the sep-
tic patients (P = 0.08), especially in those with septic shock
(median 53.25 ng/ml versus 35.13 ng/ml in non-shock
patients, P = 0.004). Previous studies of MS and athero-
sclerosis found that women have higher circulating
A-FABP levels. In this cohort of critically ill patients, there
was still a trend for a gender difference in A-FABP con-
centrations (median 53.3 ng/ml in women versus 39.1 ng/
ml in men, P = 0.057). Another important point that
needs to be mentioned is that pre-existing diabetes
patients did not have higher A-FABP concentrations than
non-diabetic patients (median 43.6 ng/ml in diabetes ver-
sus 40.9 ng/ml in non-diabetes, P = 0.74), and there was
no significant association between body mass index (BMI)
and A-FABP (rho = -0.02, P = 0.83; Table 3). In subgroup
analysis based on disease etiologies, there was no signifi-
cant difference in serum A-FABP concentration within
different disease etiologies (data not shown).
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The correlations between circulating A-FABP and other
well-known parameters are shown in Table 3. These para-
meters included markers of inflammation, sepsis, organ
dysfunction, tissue perfusion and metabolism. Serum A-
FABP was correlated positively with procalcitonin (rho =
0.26, P = 0.004) and lactic acid (rho = 0.29, P = 0.002),
markers of bacterial infection and tissue hypoperfusion.
With respect to inflammatory biomarkers, A-FABP was
correlated with TNF-alpha (rho = 0.47, P < 0.0001), but
not IL-6 and CRP. Renal failure was associated with ele-
vated serum A-FABP, as A-FABP was correlated with
creatinine (rho = 0.42, P < 0.0001). Albumin, a marker of
hepatic biosynthetic capacity, was negatively correlated
with A-FABP level (rho = -0.30, P = 0.0017). For the total
patient cohort, A-FABP level was correlated with insulin
resistance, as calculated by the HOMA-IR (rho = 0.24, P =
0.048) and fasting glucose (rho = 0.28, P = 0.0025).
Cholesterol, a marker of lipid metabolism, was found to be
inversely correlated with serum A-FABP (rho = -0.28, P =
0.0096). Most importantly, A-FABP was significantly
correlated with the APACHE II score (rho = 0.42, P <
0.0001), a well-known scoring system in disease severity
grading. After multivariate analysis, serum creatinine, fast-
ing glucose, total cholesterol, TNF-alpha, albumin, and
APACHE II score were still independently associated with
A-FABP.
Cox regression analyses and Kaplan-Meier curves were
used to assess the association of A-FABP with ICU and
hospital survival (Figure 1). We identified a lower A-FABP








Male, number (%) 74 (62%) 47 (63%) 27 (60%)
Age, median (y)ear 74 (58.5, 82.5) 76 (63, 83.5) 70.5 (52, 80.5)
BMI, median (m2/kg) 22.7 (20.2, 24.8) 21.6 (19.5, 23.8) 23.9 (21.7, 27.4)
Hypertension, number (%) 58 (48%) 37 (51%) 21 (44%)
Preexisting diabetes, number (%) 46 (38%) 30 (42%) 16 (33%)
Smoking, number (%) 55 (46%) 35 (49%) 20 (42%)
Cardiovascular disease, number (%) 37 (31%) 21 (29%) 16 (33%)
APACHE II score, median 18 (13, 25) 20.5 (16, 26) 14 (12, 22)
ICU days, median 7 (3, 14) 7 (4, 14.5) 6 (3, 13)
Hospital days, median 15 (9, 26) 18.5 (10, 30) 13 (8, 20)
Death during ICU, number (%) 14 (11.7%) 13 (17.3%) 1 (2.2%)
Death before discharge, number (%) 20 (16.7%) 17 (22.7%) 3 (6.7%)
Mechanical ventilation, number (%) 62 (51.7%) 38 (50.7%) 24 (53.3%)
Ventilation time, median (days) 10 (6.5, 24.5) 10.5 (8, 22.5) 9.5 (5, 35)
Fasting glucose, median (mg/dl) 165 (115, 234) 171 (117, 234) 159 (115, 217)
Insulin, median (uIU/ml) 16 (10.8, 22.7) 18.1 (10.8, 23.1) 12.4 (9.1, 22.5)
Creatinine, median (mg/dl) 1.5 (1, 2.25) 1.7 (1.1, 2.6) 1.2 (0.9, 1.8)
Albumin, median (g/dl) 2.9 (2.5, 3.3) 2.7 (2.4, 3.1) 3.3 (2.8, 3.7)
Alkaline phosphatase, median (mg/dl) 26 (17, 41) 25 (16.5, 40) 26.5 (17.5, 42)
C-reactive protein, median (mg/dl) 10.55 (3.38, 23) 13.4 (7.59, 25.8) 5.36 (1.17, 8.08)
TNF-alpha, median (pg/ml) 3.44 (2.08, 7.73) 4.76 (2.57, 9.84) 2.77 (1.50, 3.92)
IL-6, median (pg/ml) 8.89 (6.69, 22.58) 7.87 (6.61, 24.79) 9.80 (7.14, 19.25)
Lactic acid, median (mmol/l) 3.3 (2.1, 5.9) 3.6 (2.5, 6.2) 2.5 (1.5, 5.4)
Procalcitonin, median (ug/l) 1.53 (0.25, 9.90) 4.04 (0.54, 14.03) 0.57 (0.10, 2.06)
A-FABP, median (ng/ml) 43.3 (25.7, 67.2) 46.2 (31.9, 70.2) 38.5 (17.1, 64.3)
A-FABP, adipocyte fatty-acid binding protein; APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index.
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level upon admission to the ICU as a prognostic marker
for hospital survival in critically ill patients (hazard ratio
(HR) 3.92, 95% CI 1.15 to 13.40, P = 0.029), especially in
the sepsis patient group (HR 4.82, 95% CI 1.10 to 21.10,
P = 0.037). Kaplan-Meier curves, using a cutoff value for
serum A-FABP of 40 ng/ml, revealed significantly
improved hospital survival for critically ill patients with
low A-FABP levels upon admission to the ICU. We next
tested whether A-FABP was an independent prognostic
indicator of mortality in the group of critically ill patients
with sepsis. Multivariate Cox regression analyses using
A-FABP, APACHE II score and lactic acid as discrimina-
tors, revealed that a higher serum A-FABP level was still
an independent predictor of worse hospital survival (HR
4.59, 95% CI 1.02 to 20.6, P = 0.047).
Discussion
Our findings demonstrate that elevated serum A-FABP
concentrations in patients with critical illness were posi-
tively correlated with APACHE II scores, inflammatory
cytokine TNF-alpha and insulin resistance. Moreover,
higher A-FABP concentrations independently predicted
worse hospital outcome in patients with sepsis. Several
adipokines, including adiponectin, retinol binding protein
4 (RBP4), resistin and leptin, were studied in critically ill
patients by Koch et al. [20-23]. However, these results
were inconsistent. Serum RBP4 and resistin concentra-
tions in critically ill patients were different from normal
controls, but adiponectin and leptin concentrations were
not. The inflammatory biomarkers were correlated with
RBP4, resistin and leptin concentrations, but not with
adiponectin. The only common factor among these adi-
pokines was that they were all associated with glucose or
HOMA-IR, which reflects their well-known and domi-
nant roles in insulin resistance.
In recent studies, A-FABP was found to be expressed in
the ovary, spleen, bronchial epithelial cells, endothelial
cells and keratinocytes, as well as some tumor cells [24].
Because adipose tissue is considered to be the main source
of circulating A-FABP, we believe that upregulation of
A-FABP expression and/or increased secretion from the
adipose tissue contributes to elevated levels in patients
with critical illness. It is supported by Jernas’ study, which
demonstrates that adipose tissue gene expression changes
in patients with critical illness [25]. Another study by Han
also showed that intermittent hypoxia induced A-FABP
expression in endothelial cells [26]. The mechanism by
which cytoplasmic A-FABP is released into circulation is
also an unresolved question. Nevertheless, other FABPs in
the serum are considered to be biochemical markers of tis-
sue injury in related cells that produce FABP proteins:
Table 3 Univariate and multivariate analyses of A-FABP
concentrations with other parameters in all patients with
critical illness.
Univariate Multivariate
rho P rho P
Age 0.24 0.0085 0.11 0.41
BMI -0.02 0.83
Creatinine 0.42 < 0.0001 0.40 0.001
Fasting glucose 0.28 0.0025 0.31 0.04
HOMA-IR 0.24 0.038
Total cholesterol -0.28 0.0096 -0.26 0.04
Triglyceride 0.16 0.14
CRP 0.10 0.43
TNF-alpha 0.47 < 0.0001 0.51 < 0.0001
IL-6 -0.10 0.286
Procalcitonin 0.26 0.004 0.25 0.05
Lactic acid 0.29 0.002 0.17 0.18
Albumin -0.30 0.0017 -0.34 0.007
APACHE II score 0.42 < 0.0001 0.31 0.016
Rho and P value by Spearman rank correlation. Variables included in
multivariate analysis are age, creatinine, fasting glucose, total cholesterol, TNF-
alpha, procalcitonin, lactic acid, albumin, and APACHE II score. A-FABP,
adipocyte fatty-acid binding protein; APACHE II, Acute Physiology and Chronic
Health Evaluation; BMI, body mass index; CRP, C-reactive protein; HOMA-IR,
homeostasis model assessment index of insulin resistance.
Figure 1 Prognostic relevance of serum A-FABP concentrations in critically ill patients presented by Kaplan-Meier survival curves. In
ICU mortality analysis, the short-term mortality difference is not statistically significant between patients with higher and lower A-FABP
concentrations (A-FABP cutoff value 40 ng/ml) (a). However, higher A-FABP levels do predict worse overall hospital outcome (b), especially in
patients with sepsis (c). P values from Cox regression analysis are given. A-AFBP, adipocyte fatty-acid binding protein.
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heart FABP for acute myocardial infarction, brain FABP
for brain injury, intestinal FABP for intestinal damage
[27,28]. In sepsis, elevated serum heart FABP and urinary
liver FABP levels are believed to indicate myocardial and
kidney injury as well [29,30]. Since the A-FABP level is
higher in septic shock patients and positively correlated
with lactic acid, the elevated A-FABP in critical illness
might also reflect hypoperfusion and injuries to adipose
tissues. The upregulation of A-FABP might impair nitric
oxide production, suppress cardiomyocyte contraction and
further deteriorate the hemodynamics [31,32]. However, it
is well established that serum A-FABP is increased in
patients with chronic renal failure, making renal clearance
a relevant confounding factor for serum A-FABP concen-
trations. In our multivariate analysis, creatinine was inde-
pendently correlated with serum A-FABP, indicating that
impaired renal excretion is an important mechanism regu-
lating A-FABP.
Our results also showed a positive correlation between
serum A-FABP and fasting glucose and HOMA-IR, which
has also been found in patients with MS. Indeed, data
from basic and clinical studies have proved that circulating
A-FABP is not only a biomarker of MS but is also involved
in the pathogenesis of insulin resistance. The A-FABP
concentrations in our study were not associated with pre-
existing diabetes and BMI. These findings are in agree-
ment with our theory that circulating A-FABP reflects
critical illness-related insulin resistance. The development
of insulin resistance in critical illness seems to be an adap-
tive response to infection or stress, whereby energy
reserves are directed to where they are most needed,
namely, the immune response. Interestingly, our data
demonstrate a positive correlation of circulating A-FABP
with TNF-alpha and procalcitonin, and we believe that
bacterial infection might be a more important contributor
than stress alone. In fact, inflammatory cytokines (for
example, TNF-alpha) and Toll-like receptor 4 (TLR4), an
obligatory receptor for bacterial LPS, are important parti-
cipants in insulin resistance in critical illness. After free
fatty acid and LPS binding to TLR4, A-FABP is known to
be up-regulated in adipocytes and macrophages, which
further increases TNF-alpha expression [33]. This offers
another hint that A-FABP might be an important media-
tor between inflammation and insulin resistance in sepsis.
Since statin treatment is known to decrease serum A-
FABP levels in patients with hyperlipidemia [34], it is of
interest to evaluate the possible benefits of statin treat-
ment in sepsis through A-FABP regulation.
There are several limitations to our study. First, the
observational study design and cross sectional data failed
to clarify the causal relationship of A-FABP and sepsis.
Administration of specific A-FABP antagonists in the
animal model of sepsis may be helpful to answer this
question. Second, there is an obvious ICU mortality
difference between that found in routine clinical practice
(around 20%) and that observed in our patients. This is
because patients in the most serious condition were
more likely to refuse to join our study. Some even
refused invasive treatment and cardiopulmonary resusci-
tation. We also failed to obtain blood samples from
patients who died on the day of ICU admission. There-
fore, further studies are required to confirm our findings
and to extend the conclusions to all critically ill patients.
Third, all of these critically ill patients received suitable
treatment from the emergency department, including
antibiotics, fluid resuscitation, and inotropic agents.
Most blood samples were collected around 12 to 48
hours after ICU admission. It is thus impossible to
neglect the impact of different therapeutic agents on
serum A-FABP concentrations.
Conclusions
Our study has demonstrated that critically ill patients
have higher serum A-FABP concentrations, which are
correlated with markers of sepsis, renal function, tissue
perfusion and insulin resistance. We offer evidence that
A-FABP might act as a link between acute inflammation
and altered metabolic homeostasis. Because higher
A-FABP within 48 hours of ICU admission indepen-
dently predicts a worse hospital outcome, it serves as a
novel biomarker for all critically ill patients.
Key messages
• Adipocyte fatty-acid binding protein (A-FABP),
one of the most abundant intracellular lipid trans-
port proteins in mature adipocytes and macrophages,
was established as a link between inflammation and
insulin resistance.
• A-FABP serum concentrations are elevated in criti-
cally ill patients, and are correlated with disease
severity.
• In critical illness, A-FABP is associated with fasting
glucose and HOMA-IR, but not with pre-existing
diabetes or obesity.
• A-FABP correlates with TNF-alpha, procalcitonin
and lactic acid, but not CRP.
• A-FABP is an independent prognostic factor for
hospital survival in critically ill patients with sepsis.
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